Amgen (AMGN): FY25 Q4 earnings call, Feb 3, 2026
No Kalshi or Polymarket word markets were listed for Amgen’s Feb 3, 2026 earnings call (FY25 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
6 matches for “Oral”; 5 quoted, at least 25 words apart.
…diabetes, and obesity-related conditions. In a field featuring dozens of potential daily oral and weekly injectable medicines, Meritide stands alone as the only therapy in…
…based as well as non-incretin based. Of both injectable as well as oral medicines. And the aperture is always open. For innovation on the outside.…
…and how you're thinking about potential impact from the launch of Merck's oral PCSK9 and how you're adapting your commercial strategy there? Thank you. With…
…of that disease. In my medical training, practice with insulin and insufficient orals and titrating dosing and here we have a medicine that can be…
…actually see that in a fairly dramatic way with the advent of oral sema and how rapidly it's been taken up in the market that…
Agents: this page as TSV at /api/v1/appearances/amgen:2026-02-03:earnings_call · words: /api/v1/brief?appearance=amgen:2026-02-03:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP